<DOC>
	<DOCNO>NCT00012220</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know gemcitabine effective give alone combination another chemotherapy drug treat cancer pancreas . PURPOSE : Randomized phase II trial compare effectiveness gemcitabine give alone combination chemotherapy drug treat patient metastatic cancer pancreas .</brief_summary>
	<brief_title>Gemcitabine Alone Combination With Other Chemotherapy Drugs Treating Patients With Metastatic Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival rate patient metastatic pancreatic cancer treat gemcitabine alone vs cisplatin v docetaxel vs irinotecan . - Compare time disease progression patient treat regimen . - Compare CA 19-9 biomarker response patient treat regimen . - Correlate CA 19-9 biomarker response survival patient treat regimen . - Compare toxicity regimens patient . - Compare response patient measurable disease treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize one four treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 follow cisplatin IV 30 minute day 1 15 . Treatment repeat every 28 day least 2 course absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine IV 150 minute day 1 , 8 , 15 . Treatment repeat every 28 day least 2 course absence disease progression unacceptable toxicity . - Arm III : Patients receive gemcitabine IV 30 minute follow docetaxel IV 60 minute day 1 8 . Treatment repeat every 21 day least 3 course absence disease progression unacceptable toxicity . - Arm IV : Patients receive gemcitabine IV 30 minute follow irinotecan IV 90 minute day 1 8 . Treatment repeat every 21 day least 3 course absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year every 6 month 3 year . PROJECTED ACCRUAL : A total 240 patient ( 60 per arm ) accrue study within 30 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma pancreas Metastatic disease CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : CTC 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN SGOT great 1.5 time ULN Alkaline phosphatase value SGOT le 1.5 time ULN Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No currently active malignancy ( complete therapy consider less 30 % risk relapse ) except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Chemotherapy : No prior chemotherapy except fluorouracil ( 5FU ) At least 2 week since prior 5FU No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except steroid adrenal failure , hormonal therapy nondisease relate condition ( e.g. , insulin diabetes ) , intermittent use dexamethasone antiemetic Radiotherapy : At least 2 week since prior radiotherapy No concurrent palliative radiotherapy except wholebrain irradiation CNS disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>